Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer

BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Xia LIU, Diansheng ZHONG
Формат:	Artigo
Хэл сонгох:	Chinês
Хэвлэсэн:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-09-01
Цуврал:	Chinese Journal of Lung Cancer
Нөхцлүүд:	Lung neoplasms V-raf murine sar-coma viral oncogene homolog B1 Immune checkpoint inhibitor therapy
Онлайн хандалт:	http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.06
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!